Patents Examined by Jean C. Witz
-
Patent number: 8703716Abstract: The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements.Type: GrantFiled: March 11, 2011Date of Patent: April 22, 2014Assignee: DSM IP Assets B.V.Inventors: John P. Zimmer, Christopher M. Butt
-
Patent number: 8680045Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: GrantFiled: November 1, 2011Date of Patent: March 25, 2014Assignee: PeptiMed, Inc.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Patent number: 8673847Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: GrantFiled: October 5, 2010Date of Patent: March 18, 2014Assignee: The Medical College of Wisconsin, Inc.Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
-
Patent number: 8673849Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives.Type: GrantFiled: May 31, 2011Date of Patent: March 18, 2014Assignee: ROTALACTIS SrlInventors: Amedeo Conti, David Lembo, Claudio Fabris, Enrico Bertino, Santo Landolfo
-
Patent number: 8623377Abstract: The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein.Type: GrantFiled: June 29, 2012Date of Patent: January 7, 2014Assignee: University of Maryland, BaltimoreInventors: Kamal Moudgil, Ying-hua Yang
-
Patent number: 8580852Abstract: The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA 2 and GVIA 1PLA 2) and one human secretory phospholipase A2 (GV sPLA 2) were evaluated. Derivatives containing a free carboxyl group are selective GIVA cPLA 2 inhibitors. A derivative based on the ethyl ester of an ether pseudodipeptide is the first 2-oxoamide, which preferentially inhibits GVIA iPLA 2. The effect of 2-oxoamides on the generation of arachidonic acid from RAW 264.7 macrophages was also studied. It was found that selective GIVA cPLA 2 inhibitors preferentially inhibited cellular arachidonic acid release; in which one pseudodipeptide gave an IC50 value of 2 ?M.Type: GrantFiled: April 19, 2010Date of Patent: November 12, 2013Assignee: The Regents of the University of CaliforniaInventors: Edward A. Dennis, George Kokotos, Violetta Constantinou-Kokotou
-
Patent number: 8557771Abstract: Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs.Type: GrantFiled: March 15, 2010Date of Patent: October 15, 2013Assignee: Chongqing Fagen Biomedical Inc.Inventors: Kai Fan, Zhiquan Zhao, Yong Chen, Chun Zhang, Lin Wang
-
Patent number: 8546525Abstract: The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code.Type: GrantFiled: November 20, 2010Date of Patent: October 1, 2013Assignee: Christian-Albrechts-Universität zu KielInventor: Joachim Grötzinger
-
Patent number: 8529890Abstract: Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance.Type: GrantFiled: March 23, 2010Date of Patent: September 10, 2013Assignee: NTNU Technology Transfer ASInventors: Kurt Ingar Draget, Catherine Taylor
-
Patent number: 8492517Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: GrantFiled: May 16, 2012Date of Patent: July 23, 2013Assignee: Palatin Technologies, Inc.Inventors: Wei Yang, Yi-Qun Shi
-
Patent number: 8481482Abstract: Methods of using portions of the N-terminal domain of prion protein for binding hemin are disclosed. In a particular embodiment, a method comprises administering at least one isolated amino acid sequence comprising a peptide from the octarepeat region of PrPC to a solution containing hemin, wherein the isolated amino acid sequence is effective for forming one or more chemical bonds with hemin.Type: GrantFiled: April 13, 2012Date of Patent: July 9, 2013Assignee: The Florida State University Research Foundation, Inc.Inventor: Ewa Bienkiewicz
-
Patent number: 7803396Abstract: A product controlling dissolving rate of biomedical orthopedic implant material and a process of manufacturing the same are disclosed. At constant temperature and humidity and under vacuum, treatment solution is forced to diffuse to the material to form a second phase as a means of controlling the dissolving rate. Different treatment solution can form the phases having different structures from that of matrix. The inventive product has a structure of laminate concentric circle. The second phase and the structure of laminate concentric circle are used as ways for medicine release.Type: GrantFiled: October 17, 2006Date of Patent: September 28, 2010Inventor: Chin-Chi Yeh
-
Patent number: 7763279Abstract: A process for the production of CS particles (10) and microcapsules (12) is described, in which at least one active compound (4) is adsorbed in porous templates (2) (A), as a result of which templates (5) filled with active compounds are present. Subsequently, the templates (2) are provided (B) with a primer layer (6) which is intended to facilitate the subsequent construction of the capsule shell (9). The capsule shell is formed (C) by applying alternately charged polyelectrolyte layers (8). Filled CS particles (10) are obtained. By subsequent dissolution of the templates (2) the active compounds (4) are released (D) from the template into the interior of the microcapsules. The active compounds (4) remain enclosed there or are slowly released (E) from the capsule.Type: GrantFiled: March 16, 2005Date of Patent: July 27, 2010Assignee: Capsulution Pharma AGInventors: Lars Dahne, Barbara Baude
-
Patent number: 7759368Abstract: A sustained release composition for oral administration of niacin, comprising niacin; a carrier for sustained release composed of a hydrophilic polymer and a hydrophobic polymer; and a pharmaceutically acceptable additive, the hydrophilic polymer being a polyethylene oxide and a natural gum, is capable of maintaining a constant release rate of niacin.Type: GrantFiled: May 27, 2005Date of Patent: July 20, 2010Assignee: Hanmi Pharm. Co., LtdInventors: Jong Soo Woo, Young Hun Kim
-
Patent number: 7723387Abstract: A dermatologic peel comprising alpha hydroxyl acid and metal hydroxide nanocomplexes as neutralizing agents to continually reduce the activity of the system when the acid and neutralizer components are mixed. For example, a 30% glycolic acid gel mixed with a fluidized magaldrate neutralizer can be applied to the skin and will self-neutralize to a skin-compatible pH within a few minutes, effectively exfoliating the skin without a separate neutralization step. The peel is advantageously applied from a two-component system that mixes the components.Type: GrantFiled: October 26, 2006Date of Patent: May 25, 2010Assignee: Polymer Surfaces Group, LLCInventors: Robert MacDonald Smith, Otto William Wendel, Archie McBride
-
Patent number: RE49238Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).Type: GrantFiled: August 19, 2020Date of Patent: October 11, 2022Assignee: Retrotope, Inc.Inventor: Mikhail S. Shchepinov
-
Patent number: RE49431Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-? using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2?-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.Type: GrantFiled: August 11, 2020Date of Patent: February 28, 2023Assignee: NITTO DENKO CORPORATIONInventors: Kenjirou Minomi, Hirokazu Takahashi, Erika Terada, Jens Harborth, Jun Zhang, Mohammad Ahmadian, Wenbin Ying
-
Patent number: RE49495Abstract: The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55). The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55), and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.Type: GrantFiled: April 6, 2020Date of Patent: April 18, 2023Assignee: AFFIBODY ABInventors: Erik Nordling, Joakim Nilsson, Patrik Strömberg
-
Patent number: RE49501Abstract: Cyclodextrin compositions including one or more radiation polymerizable monomers and a cyclodextrin inclusion complex, the cyclodextrin inclusion complex including a cyclodextrin compound and an olefinic inhibitor of an ethylene generation in produce, are coated onto packaging materials and cured. Treated containers and treated package inserts having the cured cyclodextrin compositions are useful in packaging of respiring plant materials.Type: GrantFiled: January 14, 2021Date of Patent: April 25, 2023Assignee: Verdant Technologies, LLCInventors: Willard E. Wood, William J. Kuduk, Joseph S. Keute
-
Patent number: RE49522Abstract: Antimicrobial and antithrombogenic polymer or polymeric blend, compounds, coatings, and materials containing the same, as well as articles made with, or coated with the same, and methods of making the same exhibiting improved antimicrobial properties and reduced platelet adhesion. Embodiments include polymers with antimicrobial and antithrombogenic groups bound to a single polymer backbone, an antimicrobial polymer blended with an antithrombogenic polymer, and medical devices coated with the antimicrobial and antithrombogenic polymer or polymeric blend.Type: GrantFiled: February 11, 2021Date of Patent: May 9, 2023Assignee: BIOINTERACTIONS LTD.Inventors: Simon Onis, Fanny Burrows, Krishan Kapoor, Alan Rhodes, Ajay Luthra